电邮这篇文章 Recent trends in and new data on the epidemiology and prevention of non-communicable diseases
- 作者: Boytsov SA1
-
隶属关系:
- «Государственный научно-исследовательский центр профилактической медицины» Минздрава России
- 期: 卷 88, 编号 1 (2016)
- 页面: 4-10
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31898
- ID: 31898
如何引用文章
全文:
详细
Mortality from non-communicable diseases (NCDs) in the country varies considerably among its regions and social strata of the population. The main reason for providing inadequate conditions for a healthy lifestyle is that the state and municipal authorities and employers pay insufficient attention to the role of socioeconomic risk factors for NCDs. Only an analysis of the reasons for changing mortality rates allows the correct course of actions to reduce mortality to be chosen and a national plan for the control of NCDs to be worked out. The important mechanisms for improving the prevention of NCDs are to make better cardiovascular risk stratification systems, to introduce telemonitoring the status of the patients followed up, and to interface the prophylactic medical examination of elderly patients with a geriatric service. The design of long-acting drugs is a promising way to increase the patients’ motivation to control blood pressure and blood cholesterol levels.
作者简介
S Boytsov
«Государственный научно-исследовательский центр профилактической медицины» Минздрава РоссииМосква, Россия
参考
- Бойцов С.А. Механизмы снижения смертности от ишемической болезни сердца в разных странах мира. Профилактическая медицина. 2013;5:9-19.
- Бойцов С.А., Самородская И.В., Третьяков В.В., Ватолина М.А. Потерянные годы жизни в результате преждевременной смерти и их взаимосвязь с климатическими и социально-экономическими показателями регионов. Вестник Российской академии медицинских наук. 2015; 4(70):456—463.
- Промежуточный отчет о социальных детерминантах и различиях по показателям здоровья в Европейском регионе ВОЗ 2010. Доступно по: http://www.euro.who.int
- Концевая А.В., Шальнова С.А., Баланова Ю.А., Деев А.Д., Шляхто Е.В., Бойцов С.А., Чазов Е.И. Социально-экономические градиенты поведенческих факторов риска в Российской популяции (по результатам исследования ЭССЕ-РФ). Кардиоваскулярная терапия и профилактика. 2015;4:59—67.
- Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales, 1981—2000. Circulation. 2004;109:1101-1107. doi: 10.1161/01.cir.0000118498.35499.b2.
- Bajekal M, Scholes S, Love H et al. Analysing Recent Socioeconomic Trends in Coronary Heart Disease Mortality in England, 2000—2007: A Population Modelling Study. PLoS Medicine. 2012;9:6. doi: 10.1371/journal.pmed.1001237.
- Cooney MT, Dudina A, Agostino R, Graham IM. Cardiovascular risk-estimation systems in primary prevention. Circulation. 2010;122:300-310. doi: 10.1161/circulationaha.109.852756.
- Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15-26. doi: 10.1161/01.atv.0000251503.35795.4f.
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Heart Journal. 2012;33:1635-1701. doi: 10.1093/eurheartj/ehs092.
- ACC/AHA Guideline on the assessment of cardiovascular risk. Circulation. 2014;129:S49-S73. doi: 10.1161/01.cir.0000437741.48606.98.
- Würtz P, Havulinna AS, Soininen P et al. Metabolite Profiling and Cardiovascular Event Risk: A Prospective Study of Three Population-Based Cohorts. Circulation. 2015;131(9):774-785. doi: 10.1161/circulationaha.114.013116.
- ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary. J Am Coll Cardiol. 2010;56(25):2182-2199. doi: 10.1016/j.jacc.2010.09.002.
- Clarke AJ, Cooper DN. GWAS: heritability missing in action? European Journal of Human Genetics. 2010;18:859-861. doi: 10.1038/ejhg.2010.35.
- Tennessen JA, Bigham AW, O’Connor TD et аl. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337(6090):64-69. doi: 10.1126/science.1219240.
- Мешков А.Н., Бойцов С.А., Ершова А.И. и др. Исследование АТЕРОГЕН-ИВАНОВО «Изучение особенностей развития и прогрессирования АТЕРОсклероза различной локализации, в том числе с учетом ГЕНетических и эпигенетических факторов сердечно-сосудистого риска — субисследование ЭССЕ-ИВАНОВО» — дизайн, алгоритмы биоинформационного анализа и результаты секвенирования экзомов пациентов пилотной группы. Профилактическая медицина. 2013;6:11-20.
- Carrasco MP, Salvador CH, Sagredo PG et al. Impact of patient-general practitioner short-messages-based interaction on the control of hypertension in a follow-up service for low-to-medium risk hypertensive patients: a randomized controlled trial. IEEE Trans InfTechnol Biomed. 2008;12(6):780-791. doi: 10.1109/titb.2008.926429.
- McKinstry B, Hanley J, Wild S et al. Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial. BMJ. 2013;346:f3030. doi: 10.1136/bmj.f3030.
- Zhang XL, Zhu QQ, Zhu L et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMCMed. 2015;13:123. doi: 10.1186/s12916-015-0358-8.
- Ahn CH, Choi SH. New drugs for treating dyslipidemia: beyond statins. Diabetes Metab J. 2015;39(2):87-94. doi: 10.4093/dmj.2015.39.2.87.
- Lehrer-Graiwer J, Singh P, Abdelbaky A et al. FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity. J AmColl Cardiol Img. 2015;8(4):493-494. doi: 10.1016/j.jcmg.2014.06.021.
- Nilsson J, Lichtman A, Tegui A. Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges. J Intern Med. 2015. doi: 10.1111/joim.12353.
- Tissot AC, Maurer P, Nussberger J et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371(9615):821-827. doi: 10.1016/s0140-6736(08)60381-5.
补充文件
